

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10554974	
	Filing Date		2006-03-02	
	First Named Inventor	Takagi		
	Art Unit	1614		
	Examiner Name	Kevin E. Weddington		
	Attorney Docket Number	DAISAN126511		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5130333	A	1992-07-14	Pan		
	2	5298497	A	1994-03-29	Tschollar		
	3	6414126	B1	2002-07-02	Ellsworth		

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0 671 170	EP	A1	1995-09-13	McGovern		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10554974
Filing Date		2006-03-02
First Named Inventor	Takagi	
Art Unit	1614	
Examiner Name	Kevin E. Weddington	
Attorney Docket Number	DAISAN126511	

2	0956867	EP	A1	1999-11-17	Liebel		<input type="checkbox"/>
3	9071540	JP	A	1997-03-08	Tsujita		<input type="checkbox"/>
4	95/13063	WO	A1	1995-05-18	Hirsch		<input type="checkbox"/>
5	00/45818	WO	A1	2000-08-10	Cameron		<input type="checkbox"/>
6	2004/052368	WO	A1	2004-06-24	Ohlsson		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ARITA, Y., et al., "Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB-Binding Protein and Regulates Growth Factor-Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell," Circulation 105:2893-2898, June 2002.	<input type="checkbox"/>
	2	ARITA, Y., et al., "Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity," Biochemical and Biophysical Research Communications 257(1):79-83, April 1999	<input type="checkbox"/>
	3	BALLANTYNE, C.M., et al., "Efficacy of Rosuvastatin 10 mg in Patients With the Metabolic Syndrome," American Journal of Cardiology 91(5A):25C-27C, March 2003.	<input type="checkbox"/>
	4	BERG, A.H., et al., "The Adipocyte-Secreted Protein Acrp30 Enhances Hepatic Insulin Action," Nature Medicine 7(8):947-953, August 2001.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10554974
Filing Date		2006-03-02
First Named Inventor	Takagi	
Art Unit	1614	
Examiner Name	Kevin E. Weddington	
Attorney Docket Number	DAISAN126511	

5	COMBS, T.P., et al., "Endogenous Glucose Production Is Inhibited by the Adipose-Derived Protein Acrp30," Journal of Clinical Investigation 108(12):1875–1881, December 2001.	<input type="checkbox"/>
6	DEEDWANIA, P., and D. HUNNINGHAKE, "Comparative Effects of Statins on Atherogenic Dyslipidemia in Patients With the Metabolic Syndrome," Journal of the American College of Cardiology 43(5, Suppl A):485A, March 2004 (presented at the 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, March 7–10, 2004) (Abstract 820-1).	<input type="checkbox"/>
7	DROSSOS, T., et al., "Results of Pravastatin on Metabolic Parameters of Patients With Diabetes Mellitus Type II Under Simultaneous Treatment With Glybenclamide," Atherosclerosis 144:205, May 1999 (Abstract).	<input type="checkbox"/>
8	HOTTA, K., et al., "Circulating Concentrations of the Adipocyte Protein Adiponectin Are Decreased in Parallel With Reduced Insulin Sensitivity During the Progression to Type 2 Diabetes in Rhesus Monkeys," Diabetes 50(5):1126–1133, May 2001.	<input type="checkbox"/>
9	HUNNINGHAKE, D.B., et al., "Comparative Effects of Simvastatin and Atorvastatin in Hypercholesterolemic Patients With Characteristics of Metabolic Syndrome," Clinical Therapeutics 25(6):1670–1686, June 2003.	<input type="checkbox"/>
10	INOUE, Y., et al., "A Multi-Centre Study of the Efficacy and Safety of Pravastatin in Hypercholesterolaemic Patients With Non-Insulin-Dependent Diabetes Mellitus," Current Medical Research and Opinion 13(4):187–194, 1994.	<input type="checkbox"/>
11	KADOWAKI, T., and T. YAMAUCHI, "Adiponectin and Adiponectin Receptors," Endocrine Reviews 26(3):439–451, May 2005.	<input type="checkbox"/>
12	KONDO, H., et al., "Association of Adiponectin Mutation With Type 2 Diabetes: A Candidate Gene for the Insulin Resistance Syndrome," Diabetes 51(7):2325–2328, July 2002.	<input type="checkbox"/>
13	LINDSAY, R.S., et al., "Adiponectin and Development of Type 2 Diabetes in the Pima Indian Population," Lancet 360(9326):57–58, July 2002.	<input type="checkbox"/>
14	MAEDA, K., et al., "cDNA Cloning and Expression of a Novel Adipose Specific Collagen-Like Factor, apM1 (Adipose Most Abundant Gene Transcript 1)," Biochemical and Biophysical Research Communications 221(2):286–289, 1996.	<input type="checkbox"/>
15	MAEDA, N., "PPAR γ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein," Diabetes 50(9):2094–2099, September 2001.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10554974
Filing Date	2006-03-02
First Named Inventor	Takagi
Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	DAISAN126511

16	NEWMAN, C., et al., "Efficacy of Atorvastatin in Dyslipidemic Patients With Metabolic Syndrome in the ACCESS Study," Diabetes 52(Suppl 1):A494, 2003 (presented at the 63rd Scientific Sessions of the American Diabetes Association, New Orleans, June 13–17, 2003) (Abstract 2141-PO).	<input type="checkbox"/>
17	OKAMOTO, Y., et al., "Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice," Circulation 106(22):2767–2770, November 2002.	<input type="checkbox"/>
18	OLSSON, A.G., et al., "Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor," Cardiovascular Drug Reviews 20(4):303–328, January 2002.	<input type="checkbox"/>
19	ORSI, A., et al., "Simvastatin-Associated Memory Loss," Pharmacotherapy 21(6):767–769, June 2001.	<input type="checkbox"/>
20	OUCHI, N., et al., "Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages," Circulation 103(8):1057–1063, February 2001.	<input type="checkbox"/>
21	OUCHI N., et al., "Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent Pathway," Circulation 102(11):1296–1301, September 2000.	<input type="checkbox"/>
22	OUCHI, N., "Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin," Circulation 100(25):2473–2476, December 1999.	<input type="checkbox"/>
23	PANIAGUA, J.A., et al., "Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes," Diabetes 51(8):2596–2603, August 2002.	<input type="checkbox"/>
24	REAVEN, G.M., "Banting Lecture 1988: Role of Insulin Resistance in Human Disease," Diabetes 37(12):1595–1607, December 1988.	<input type="checkbox"/>
25	ROSS, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s," Nature 362(6423):801–809, April 1993.	<input type="checkbox"/>
26	SAITO, Y., et al., "Statin Reverses Reduction of Adiponectin Receptor Expression in Infarcted Heart and in TNF-α-Treated Cardiomyocytes in Association With Improved Glucose Uptake," American Journal of Physiological: Heart and Circulatory Physiology 293(6):H3490–H3497, December 2007.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10554974
Filing Date	2006-03-02
First Named Inventor	Takagi
Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	DAISAN126511

27	SCHULZE, M.B., et al., "Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes," Diabetes 54(2):534–539, February 2005.	<input type="checkbox"/>
28	SUGIMOTO, T., "Pravastatin Versus Simvastatin in Hyperlipidemic Patients With Type 2 Diabetes Mellitus," Current Therapeutic Research 60(7):404–413, July 1999.	<input type="checkbox"/>
29	WEYER, C., et al., "Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association With Insulin Resistance and Hyperinsulinemia," Journal of Clinical Endocrinology & Metabolism 86(5):1930–1935, May 2001.	<input type="checkbox"/>
30	YAMAUCHI, T., et al., "The Fat-Derived Hormone Adiponectin Reverses Insulin Resistance Associated With Both Lipoatrophy and Obesity," Nature Medicine 7(8):941–946, August 2001.	<input type="checkbox"/>
31	YOKOTA, T., et al., "Adiponectin, a New Member of the Family of Soluble Defense Collagens, Negatively Regulates the Growth of Myelomonocytic Progenitors and the Functions of Macrophages," Blood 96(5):1723–1732, September 2000.	<input type="checkbox"/>
32	ZOCCALI, C., et al., "Adiponectin, Metabolic Risk Factors, and Cardiovascular Events Among Patients With End-Stage Renal Disease," Journal of the American Society of Nephrology 13(1):134–141, January 2002.	<input type="checkbox"/>
33	Supplementary European Search Report dated July 14, 2009, issued in corresponding European Application No. EP 04 72 9730, filed April 27, 2004.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.